Leishmania tarentolae: Utility as an in vitro model for screening of antileishmanial agents

Experimental Parasitology

Volumn 126, Issue 4, 2010, Pages 471-475

  Taylor, Viviana M ^a   Muñoz, Diana L ^a   Cedeño, David L ^b   Vélez, Iván D ^a   Jones, Marjorie A ^b   Robledo, Sara M ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b ILLINOIS STATE UNIVERSITY   (United States)

Author keywords

Antileishmanial activity; Axenic amastigotes; Drug sensitivity; Leishmania tarentolae

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTILEISHMANIAL AGENT; MEGLUMINE ANTIMONATE; RECOMBINANT PROTEIN; ANTIPROTOZOAL AGENT; MEGLUMINE; MEGLUMINE ANTIMONIATE; ORGANOMETALLIC COMPOUND;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOSAFETY; CELL STRAIN U937; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; GENE AMPLIFICATION; GENE EXPRESSION SYSTEM; GERMFREE ANIMAL; GROWTH RATE; HAMSTER; HUMAN; HUMAN CELL; IN VITRO STUDY; LEISHMANIA BRAZILIENSIS; LEISHMANIA PANAMENSIS; LEISHMANIA TARENTOLAE; LEISHMANIASIS; MACROPHAGE; MAMMAL CELL; NONHUMAN; PARASITE ISOLATION; PARASITE VIRULENCE; PRIORITY JOURNAL; PROMASTIGOTE; VALIDATION PROCESS; ANIMAL; CELL CULTURE; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; LEISHMANIA; LIZARD; MESOCRICETUS; PARASITOLOGY; PERITONEUM MACROPHAGE; PROCEDURES; U937 CELL LINE;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CELLS, CULTURED; CRICETINAE; DRUG EVALUATION, PRECLINICAL; HUMANS; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA GUYANENSIS; LIZARDS; MACROPHAGES; MACROPHAGES, PERITONEAL; MEGLUMINE; MESOCRICETUS; ORGANOMETALLIC COMPOUNDS; U937 CELLS;

EUKARYOTA; GEKKONIDAE; LEISHMANIA TARENTOLAE; MAMMALIA;

EID: 80052848652     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2010.05.016     Document Type: Article

References (28)

1. Bates P. Axenic culture of Leishmania amastigotes. Parasitology Today 1993, 9:143-146.
2. Breton M., Tremblay M.J., Ouellette M., Papadopoulou B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infection and Immunity 2005, 73:6372-6382.
3. Breton M., Zhao C., Ouellette M., Tremblay M.J., Papadopoulou B. A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection. Journal of General Virology 2007, 88:217-225.
4. Callahan H.L., Portal A.C., Devereaux R., Grogl M. An axenic amastigote system for drug screening. Antimicrobial Agents and Chemotherapy 1997, 41:818-822.
5. Chavali A.K., Whittemore J.D., Eddy J.A., Williams K.T., Papin J.A. Systems analysis of metabolism in the pathogenic trypanosomatid Leishmania major. Molecular System Biology 2008, 4:177.
6. Eperon S., McMahon-Pratt D. Extracellular cultivation and morphological characterization of amastigote-like forms of Leishmania panamensis and L. Braziliensis. Journal of Protozoology 1989, 36:502-510.
7. Finney D.J. Statistical Method in Biological Assay 1978, Academic Press, London, p. 508.
8. Fritsche C., Sitz M., Weiland N., Breitling R., Pohl H.D. Characterization of the growth behavior of Leishmania tarentolae: a new expression system for recombinant proteins. Journal of Basic Microbiology 2007, 47:384-393.
9. Gao G., Kapushoc S., Simpson A., Thiemann O., Simpson L. Guide RNAs of the recently isolated LEM125 strain of Leishmania tarentolae: an unexpected complexity. RNA 2001, 7:1335-1347.
10. Gupta N., Goyal N., Rastogi A.K. In vitro cultivation and characterization of axenic amastigotes of Leishmania. Trends in Parasitology 2001, 17:150-153.
11. Haimeur A., Ouellette M. Gene amplification in Leishmania tarentolae selected for resistance to sodium stibogluconate. Antimicrobial Agents and Chemotherapy 1998, 42:1689-1694.
12. Hodgkinson V.H., Soongs L., Monroe S., McMahon-Pratt D. Leishmania amazonensis: cultivation and characterization of axenic amastigote-like organisms. Experimental Parasitology 1996, 83:94-105.
13. Ismaeel A., Garmson J., Molyneux D., Bates P. Transformation, development, and transmission of axenically cultured amastigotes of Leishmania mexicana in vitro and in Lutzomyia longipalpis. The American Journal of Tropical Medicine and Hygiene 1998, 59:421-425.
14. Lainson R., Shaw J.J. Evolution, classification and geographical distribution of Leishmania. The Leishmaniasis in Biology and Medicine 1987, 1-120. Academic Press, London. W. Peters, R. Killick-Kendrick (Eds.).
15. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 1983, 65:55-63.
16. Robledo S.M., Valencia A.Z., Saravia N.G. Sensitivity to glucantime of Leishmania viannia isolated from patients prior to treatment. The Journal of Parasitology 1999, 85:360-366.
17. Robledo S., Osorio E., Muñoz D., Jaramillo L.M., Restrepo A., Arango G., Vélez I. In vitro and in vivo cytotoxicities and antileishmanial activities of thymol and hemisynthetic derivatives. Antimicrobial Agents and Chemotherapy 2005, 49:1652-1655.
18. Sereno D., Lemesre J.L. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrobial Agents and Chemotherapy 1997, 41:972-976.
19. Sereno D., Cavaleyra M., Zemzoumi K., Maquaire S., Ouaissi A., Lemesre J.M. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrobial Agents and Chemotherapy 1998, 42:3097-3102.
20. Sereno D., Cordeiro da Silva A., Mathieu-Daude F., Ouaissi A. Advances and perspectives in Leishmania cell based drug-screening procedures. Parasitology International 2007, 56:3-7.
21. Singh A.K., Papadopoulou B., Ouellette M. Gene amplification in amphotericin B-resistant Leishmania tarentolae. Experimental Parasitology 2001, 99:141-147.
22. Thiemann O.H., Maslov E.A., Simpson L. Disruption of RNA editing in Leishmania tarentolae by the loss of minicircle-encoded guide RNA genes. The EMBO Journal 1994, 13:5689-5700.
23. Valencia G., Vera-Ku B., Flores-Serrano F., Andrade-Narváez F. Obtención de cultivo axénico de amastigotes de tres cepas de Leishmania (Leishmania) mexicana a partir de promastigotes aislados de pacientes con leishmaniasis cutánea localizada en México. Revista Biomédica (México) 1998, 9:206-213.
24. Vannier-Santos M.A., Martiny A., De Souza W. Cell biology of Leishmania spp.: invading and evading. Current Pharmaceutical Design 2002, 8:297-318.
25. Wallbanks K.R., Maazoun R., Canning E.U., Rioux J.A. The identity of Leishmania tarentolae Wenyon 1921. Parasitology 1985, 90:67-78.
26. World Health Organization, 2004. Scientific working group report on leishmaniasis. Available from: http://www.who.int/tdrold/publications/publications/swg_leish.htm.
27. Yakovich A.J., Ragone F.L., Alfonzo J.D., Sackett D.L., Werbovetz K.A. Leishmania tarentolae: purification and characterization of tubulin and its suitability for antileishmanial drug screening. Experimental Parasitology 2006, 114:289-296.
28. Zilberstein D., Liveanu N.B., Gepstein A., Jaffe C. Growth at acidic pH induces an amastigote stage-specific protein in Leishmania promastigotes. Molecular and Biochemical Parasitology 1991, 45:175-178.